A balanced approach to psychedelic healthcare and wellness

PharmaDrug Inc. is a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. The company has three business segments:

1) In the European cannabis space, Pharmadrug is an EU-GMP approved distributor of medical cannabis in the German market with a Class 1 Narcotics license. Medical cannabis in the EU is already a €1bn market, and we are forecasting rapid growth over the next decade based on continued regulatory liberalization. In recent months Pharmadrug has added new supply agreements with cannabis producers, and we believe that these will allow the company to achieve significant volume growth during 2021 and 2022.

2) In retail psychedelics, Pharmadrug has established a retail brand focussed on the Netherlands-based market for legally sold ‘magic truffles’. During 2021 we expect significant expansion on the initial operation which is in place with material revenue generation by the second half of the year. The Dutch-based retail psychedelics operation also provides a platform for Pharmadrug to expand into other legalized psychedelics markets as and when regulatory liberalization allows.

3) Pharmadrug also has a biotech operation focussed on plant-derived pharmaceutical medicines. The company is positioning itself to become a leader in developing the medical application of the naturally occurring psychedelic, N,N-Dimethyltryptamine (DMT). Pharmadrug recently announced a research agreement with the University of Michigan to evaluate the action of DMT on normal, diseased and altered states of consciousness. This program complements the company’s existing DMT programs which focus on the anti-oxidative properties of DMT. In addition to the DMT programs, Pharmadrug is working with a plant-derived drug called Cepharanthine, outside of the psychedelic medicine space, to produce a therapy targeting esophageal cancer.

In this report, we examine the growth drivers for each of the three segments, and the overall revenue growth outlook for Pharmadrug.